Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study

Table 5

Liver-related adverse events in the two groups.

Variables	UDCA-only group (N=14)	UDCA+IS group (N=14)	P value
Adverse events	9/14(64.3%)	2/14(14.3%)	0.018
Severe ascites	4(28.6%)	1(7.1%)	0.326
Variceal bleeding	1(7.1%)	0	>0.999
Liver failure	4(28.6%)	1(7.1%)	0.596
Transplantation/liver-related death	4/14(28.6%)	1/14(7.1%)	0.326

Note. UDCA, ursodeoxycholic acid; IS, immunosuppressants.